Basheer, H.A., Salman, N.M., Abdullah, R.M., Elsalem, L. and Afarinkia, Kamyar ORCID: https://orcid.org/0000-0003-2819-4364 (2025) Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes. Translational Oncology, 53 (102323). ISSN 1944-7124

Preview

PDF Metformin and glioma - Targeting metabolic dysregulation for enhanced therapeutic outcomes_1-s2.0-S1936523325000543-main.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

Glioma, a highly aggressive form of brain cancer, continues to pose significant therapeutic challenges in the field of medicine. Its invasive nature and resistance to traditional treatments make it particularly difficult to combat. This review examines the potential of metformin, a commonly prescribed antidiabetic medication, as a promising new treatment option for glioma. The potential of metformin to target crucial metabolic pathways in cancer cells presents an encouraging approach to improve therapeutic outcomes. The review explores the complexities of metabolic reprogramming in glioma and metformin's role in inhibiting these metabolic pathways. Preclinical studies demonstrate metformin's efficacy in reducing tumor growth and enhancing the sensitivity of glioma cells to chemotherapy and radiotherapy. Furthermore, clinical studies highlight metformin's potential in improving progression-free survival and overall survival rates in glioma patients. The review also addresses the synergistic effects of combining metformin with other therapeutic agents, such as temozolomide and radiotherapy, to overcome drug resistance and improve treatment efficacy.
Despite the promising findings, the review acknowledges the need for further clinical trials to establish optimal dosing regimens, understand the molecular mechanisms underlying metforminʼs antitumor effects, and identify patient populations that would benefit the most from metformin-based therapies. Additionally, the potential side effects and the long-term impact of metformin on Glioma patients require careful evaluation.
In conclusion, this review underscores the potential of metformin as a repurposed drug in glioma treatment, emphasizing its multifaceted role in targeting metabolic dysregulation. Metformin holds promise as part of a combination therapy approach to improve the therapeutic landscape of glioma and offers hope for better patient outcomes.

Item Type:	Article
Identifier:	10.1016/j.tranon.2025.102323
Subjects:	Medicine and health > Clinical medicine > Therapeutics Medicine and health > Pharmacology
Depositing User:	Marc Forster
Date Deposited:	04 Mar 2025 09:46
Last Modified:	04 Mar 2025 10:00
URI:	https://repository.uwl.ac.uk/id/eprint/13291
Sustainable Development Goals:	Goal 3: Good Health and Well-Being

Downloads

Actions (login required)

View Item